Vector Science and Therapeutics Corp. develops innovative biomechanical devices and localized drug-delivery platforms. While the company boasts a strong liquidity position with a current ratio of 4.73 and no debt, its financial health is concerning, reflected in negative ROE and ROA figures. The stock price of $1.58, down 1.25%, raises questions about market confidence despite the potential of its technology. Overall, the company shows promise in its niche but faces significant financial challenges that could impact future growth.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Excellent liquidity with current ratio of 4.7x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Medical Devices companies of a similar size
Based on 2026-Q3 (May 31, 2026)